GERN Share Price

Open 2.19 Change Price %
High 2.25 1 Day -0.06 -2.73
Low 2.13 1 Week -0.14 -6.14
Close 2.14 1 Month 0.22 11.46
Volume 859568 1 Year -0.51 -19.25
52 Week High 3.35
52 Week Low 1.81
GERN Important Levels
Resistance 2 2.25
Resistance 1 2.21
Pivot 2.17
Support 1 2.07
Support 2 2.03
NASDAQ USA Most Active Stocks
CTRP 47.59 1.13%
ADBE 119.47 -0.13%
FSLR 33.57 -8.33%
FSLR 33.57 -8.33%
CERN 55.37 0.18%
BIDU 186.01 0.21%
AAPL 137.11 0.30%
AAPL 137.11 0.30%
FB 136.12 1.79%
MASI 87.05 2.03%
More..
NASDAQ USA Top Gainers Stocks
VALV 0.05 66.67%
LOCM 0.09 50.00%
BASI 1.33 31.68%
WRES 0.09 28.57%
INAP 2.31 27.62%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
AETI 2.40 23.08%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Geron Corporation (NASDAQ: GERN)

GERN Technical Analysis 1.5
As on 22nd Feb 2017 GERN Share Price closed @ 2.14 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.49 & Buy for SHORT-TERM with Stoploss of 2.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
GERN Target for February
1st Target up-side 2.38
2nd Target up-side 2.59
3rd Target up-side 2.8
1st Target down-side 1.78
2nd Target down-side 1.57
3rd Target down-side 1.36
GERN Other Details
Segment EQ
Market Capital 171289824.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.geron.com
GERN Address
GERN
149 Commonwealth Drive
Suite 2070
Menlo Park, CA 94025
United States
Phone: 650-473-7700
Fax: 650-473-7750
Interactive Technical Analysis Chart Geron Corporation ( GERN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Geron Corporation
GERN Business Profile
Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets.